We are live on ! Find out more
SLXP

SALIX PHARMACEUTICALS LTD DEL
SLXP

Delisted

SLXP was delisted on the 31st of March, 2015.

246 hedge funds and large institutions have $6.3B invested in SALIX PHARMACEUTICALS LTD DEL in 2013 Q4 according to their latest regulatory filings, with 32 funds opening new positions, 83 increasing their positions, 107 reducing their positions, and 36 closing their positions.

New
Increased
Maintained
Reduced
Closed

127% more call options, than puts

Call options by funds: $83.6M | Put options by funds: $36.8M

100% more funds holding in top 10

Funds holding in top 10: 36 (+3)

57% more capital invested

Capital invested by funds: $4B → $6.3B (+$2.3B)

2% less funds holding

Funds holding: 251246 (-5)

11% less first-time investments, than exits

New positions opened: 32 | Existing positions closed: 36

22% less repeat investments, than reductions

Existing positions increased: 83 | Existing positions reduced: 107

Holders
246
Holders Change
-5
Holders Change %
-1.99%
% of All Funds
7.14%
Holding in Top 10
6
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+100%
% of All Funds
0.17%
New
32
Increased
83
Reduced
107
Closed
36
Calls
$83.6M
Puts
$36.8M
Net Calls
+$46.8M
Net Calls Change
+$6.68M
Name Holding Trade Value Shares
Change
Change in
Stake
Millennium Management
26
Millennium Management
New York
$41.5M +$20.1M +251,990 +120%
ZCI
27
Zevenbergen Capital Investments
Washington
$40.8M -$4.71M -59,100 -12%
CCM
28
Century Capital Management
Massachusetts
$39.6M +$2.19M +27,445 +7%
AAMU
29
Amundi Asset Management US
Massachusetts
$36.9M -$3.39M -42,494 -9%
HM
30
HealthCor Management
New York
$36M +$31.9M +400,000 New
Norges Bank
31
Norges Bank
Norway
$35.1M +$1.88M +23,518 +6%
N
32
Nuveen
North Carolina
$29M +$4.67M +58,588 +22%
FIM
33
Foresters Investment Management
New York
$28.3M +$25.1M +314,800 New
ACM
34
Apex Capital Management
Ohio
$28.1M +$1.3M +16,313 +6%
JHIU
35
Janus Henderson Investors US
Colorado
$28M -$5.74M -71,944 -19%
O
36
OppenheimerFunds
New York
$27.8M +$24.6M +308,710 New
RIM
37
Rainier Investment Management
Washington
$27.6M -$9.19M -115,190 -27%
Geode Capital Management
38
Geode Capital Management
Massachusetts
$27.4M +$3.96M +49,683 +19%
D.E. Shaw & Co
39
D.E. Shaw & Co
New York
$27.2M +$5.6M +70,265 +30%
TCM
40
Tang Capital Management
California
$27M
First Trust Advisors
41
First Trust Advisors
Illinois
$26.8M +$373K +4,676 +2%
GC
42
Guggenheim Capital
Illinois
$26.7M +$15.2M +190,860 +181%
AAM
43
AMI Asset Management
California
$26.5M -$117K -1,464 -0.5%
New York State Common Retirement Fund
44
New York State Common Retirement Fund
New York
$26.4M -$2.1M -26,320 -8%
Renaissance Technologies
45
Renaissance Technologies
New York
$24.2M +$512K +6,419 +2%
CCM
46
Consonance Capital Management
New York
$23.2M -$2.39M -30,000 -10%
Deutsche Bank
47
Deutsche Bank
Germany
$23M +$8.05M +100,935 +65%
Adage Capital Partners
48
Adage Capital Partners
Massachusetts
$22.5M +$12M +150,000 +150%
Arrowstreet Capital
49
Arrowstreet Capital
Massachusetts
$22.1M +$11.7M +146,712 +147%
SIMG
50
Stephens Investment Management Group
Texas
$20.4M -$2.33M -29,240 -11%

SLXP Hedge Fund Activity: Q4 2013 in Review

246 of the 3,445 institutional investors tracked by Wall St. Rank reported a position in SALIX PHARMACEUTICALS LTD DEL (SLXP) for Q4 2013, worth a combined $6.3B — up 57% from $4B a quarter earlier.

Sellers outnumbered buyers: 36 funds closed out of SLXP and 32 opened new positions — a net loss of 4 holders — while 107 trimmed existing stakes and 83 added.

The largest buyer was Fidelity Investments, adding an estimated $453M. The largest seller was Bank of America, cutting an estimated $135M.

  • 246 institutional investors held SALIX PHARMACEUTICALS LTD DEL (SLXP) as of Q4 2013, down from 251 in Q3 2013.
  • Funds reported $6.3B of SALIX PHARMACEUTICALS LTD DEL stock for Q4 2013, up 57% quarter-over-quarter.
  • 32 funds opened new SALIX PHARMACEUTICALS LTD DEL positions in Q4 2013 and 36 closed out, a net change of -4 holders.
  • The largest SALIX PHARMACEUTICALS LTD DEL buyer in Q4 2013 was Fidelity Investments, an estimated $453M added.
  • The largest SALIX PHARMACEUTICALS LTD DEL seller in Q4 2013 was Bank of America, an estimated $135M sold.

Based on aggregated 13F filings for Q4 2013.